CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole (Q44273424)

1 December 2017

title

CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole (English)

1 reference

1 December 2017

1 reference

3

1 reference

1 December 2017

7

1 reference

1 December 2017

8

1 reference

1 December 2017

Johanna Weiss

1

1 reference

1 December 2017

Magdalena Maria Ten Hoevel

2

1 reference

1 December 2017

Ingeborg Walter-Sack

4

1 reference

1 December 2017

Michael Marcus Hoffmann

5

1 reference

1 December 2017

Jens Rengelshausen

6

1 reference

1 December 2017

publication date

25 November 2008

1 reference

The Journal of Clinical Pharmacology

1 December 2017

published in

1 reference

1 December 2017

volume

49

1 reference

1 December 2017

issue

2

1 reference

1 December 2017

page(s)

196-204

1 reference

Identification of the Cytochrome P450 Enzymes Involved in theN-Oxidation of Voriconazole

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270008327537

The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008327537

Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008327537

Clinical relevance of genetic polymorphisms in the human CYP2C subfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008327537

Effect of omeprazole on the steady‐state pharmacokinetics of voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008327537

Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008327537

Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008327537

A Candida albicans petite mutant strain with uncoupled oxidative phosphorylation overexpresses MDR1 and has diminished susceptibility to fluconazole and voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008327537

Development and validation of a high-performance liquid chromatography assay for voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008327537

Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008327537

Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008327537

CYP3A5 phenotype-genotype correlations in a British population

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008327537

Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008327537

ABCB1 pharmacogenetics: progress, pitfalls, and promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008327537

Inhibition of P-glycoprotein by newer antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008327537

Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008327537

Evaluation of inhibitory potencies for compounds inhibiting P-glycoprotein but without maximum effects: f2 values

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008327537

Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008327537

Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008327537

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008327537

Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008327537

Genotype???phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008327537

Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008327537

Factors affecting cytochrome P-450 3A activity in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008327537

CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008327537

CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008327537

Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008327537

Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008327537

Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008327537

Potent cytochrome P450 2C19 genotype–related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008327537

Pharmacology of Systemic Antifungal Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008327537

21 January 2018

Identifiers

DOI

10.1177/0091270008327537

1 reference

release_xzul7g6hincotfo3r4che3zux4

1 December 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xzul7g6hincotfo3r4che3zux4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference